跳至主要内容
临床试验/NCT05739110
NCT05739110已完成不适用

Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study

Zhejiang University1 个研究点 分布在 1 个国家目标入组 1,100 人开始时间: 2022年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,100
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • primary and histologically confirmed HCCs
  • patients who underwent curative liver resection

排除标准

  • simultaneous presence of other tumors
  • patients who had received preoperative antitumor therapies
  • no available surgical specimens for evaluating micronecrosis status
  • gross tumor necrosis and Nscore = 3

结局指标

主要结局

Overall survival

时间窗: from date after liver resection until death or last follow-up, whichever came first, assessed up to 72 months

the number of months from the date of surgery to the date of the last follow-up visit or time of death.

次要结局

  • Disease-free survival(from date after liver resection until recurrence or last follow-up, whichever came first, assessed up to 72 months)

研究者

发起方
Zhejiang University
申办方类型
Other
责任方
Principal Investigator
主要研究者

TingBo Liang

Director

Zhejiang University

研究点 (1)

Loading locations...

相似试验